

Procore Technologies reported Q2 revenue of $375.2 million and EPS of $0.47, both beating consensus estimates. The company did not provide a management comment with the preliminary release. Procore's Q2 performance extends a streak of top-line beats as the construction software provider benefits from steady subscription adoption across its customer base. | Metric | Actual | Consensus | Beat/Miss | |--------|--------|-----------|-----------| | Revenue | $375.2M | $373.2M | +0.55% | | EPS | $0.47 | $0.43 | +10.3% | Revenue of $375.2 million exceeded the $373.2 million consensus by 0.55%, while EPS of $0.47 topped the $0.43 estimate by 10.3%. The company did not disclose updated guidance or specific annual recurring revenue metrics in the release. Prior-year comparable figures were not yet available in the filing. The NYSE-listed construction software provider competes with Autodesk Inc. and Oracle Corp. in the project management space. Procore has focused on expanding its platform beyond core project management into financials and workforce planning to drive per-customer revenue growth. The strategy aims to increase wallet share among existing customers rather than relying solely on new logo acquisition. Construction technology adoption has been a steady tailwind as general contractors digitize project workflows. The results show that demand for construction management software remains resilient even as enterprise software spending faces pressure from higher interest rates. Procore's next event is the Q3 earnings call, where investors will look for updates on customer count growth and net retention rates, two key SaaS metrics that indicate platform stickiness. This article is for informational purposes only and does not constitute investment advice.

Peabody Energy reported Q2 revenue of $1 billion, missing estimates, as coal demand weakened. "Coal markets remain challenging as utilities reduce thermal coal consumption," the company said in its earnings release. The St. Louis-based coal producer posted an adjusted loss of $0.74 a share, compared with the consensus estimate for a loss of $0.38. Revenue of $1 billion fell short of the $1.03 billion analysts had projected, according to data compiled by Bloomberg. | Metric | Actual | Consensus | Beat/Miss | |--------|--------|-----------|-----------| | Revenue | $1.00B | $1.03B | -2.6% | | EPS | -$0.74 | -$0.38 | -$0.36 | The miss reflects pressure on Peabody as US utilities reduce coal consumption in favor of natural gas and renewable energy. The company, one of the largest US coal producers, operates both thermal and metallurgical coal mines across the US and Australia. The EPS miss of $0.36 per share was driven by weaker-than-expected revenue and potentially higher operating costs. Peabody did not provide updated full-year guidance in its earnings release, leaving investors to assess the trajectory of coal markets on their own. The company faces headwinds on multiple fronts. Thermal coal demand continues to decline as US power generators shift to cheaper natural gas and subsidized renewable capacity. On the metallurgical coal side, softer global steel production has weighed on pricing for the high-grade coal used in blast furnaces. Peabody's results come as the coal sector contends with a prolonged structural downturn. The company's diversified geographic footprint, with operations in both the US and Australia, provides some buffer but does not insulate it from broader market trends. The results highlight the challenges facing US coal producers as the energy transition reshapes power markets. Investors will watch for Peabody's Q3 production update and any changes to its full-year guidance. The next catalyst for the stock will be the company's Q3 earnings report, expected in late October. This article is for informational purposes only and does not constitute investment advice.

uniQure reported Q2 revenue of $5.84 million, beating estimates, while its per-share loss of $1.22 missed consensus by 45 percent. The gene therapy company did not provide executive commentary alongside the results. Revenue of $5.84 million came in 4.7 percent above the $5.58 million consensus estimate, while the adjusted loss of $1.22 per share compared with analyst expectations for a loss of $0.84. The mixed results highlight the challenge uniQure faces as it commercializes its gene therapy pipeline while managing operating expenses. The wider-than-expected loss may raise questions about the company's cost structure and cash burn rate heading into the second half of 2026. Shares of uniQure moved in after-hours trading following the release. The company's next catalyst will be its quarterly update on pipeline progress and any updates on its commercial gene therapy programs. This article is for informational purposes only and does not constitute investment advice.